Andrea Knezevic, MS

Research Biostatistician II

Epidemiology & Biostatistics
Directory
Epidemiology
Biostatistics
Health Outcomes
Computational Oncology
Administrative Resources
Departmental Newsletter
Career Opportunities
Quantitative Sciences Undergraduate Research Experience (QSURE)
Software
Bridge to Biostats

Andrea Knezevic, MS

Research Biostatistician II

Share
Share
Andrea Knezevic

Email

[email protected]

Education

Georgia Institute of Technology

Current Research Interest

Andrea Knezevic joined Memorial Sloan Kettering in 2017, following 8 years of research at the Emory University Department of Biostatistics & Bioinformatics. Andrea has experience in design, implementation and analysis of clinical trials, as well as retrospective and prospective observational studies. Her analytical expertise is in survival analysis and model building for explanatory and predictive modeling. Her primary clinical collaborations at MSKCC are with oncologists in the Genitourinary Service. Andrea’s biostatistical research interests include survival analysis in the presence of non-proportional hazards and methods for handling incomplete outcome data in competing risks analysis. Andrea serves as a Co-Chair of the Biostatistics Protocol Review Committee (BPRC), and leads the Biostatistics Master’s Seminar Series. She serves as an invited statistical reviewer for the Journal of the National Cancer Institute (JNCI) and JNCI Cancer Spectrum.

Publications

  1. Lee CH, Voss MH, Carlo MI, Chen YB, Zucker M, Knezevic A, Lefkowitz RA, Shapnik N, Dadoun C, Reznik E, Shah NJ, Owens CN, McHugh DJ, Aggen DH, Laccetti AL, Kotecha R, Feldman DR, Motzer RJ. Phase II Trial of Cabozantinib Plus Nivolumab in Patients With Non-Clear-Cell Renal Cell Carcinoma and Genomic Correlates. J Clin Oncol. 2022 Mar 17;:JCO2101944. doi: 10.1200/JCO.21.01944.
  2. Feldman DR, Ged Y, Lee CH, Knezevic A, Molina AM, Chen YB, Chaim J, Coskey DT, Murray S, Tickoo SK, Reuter VE, Patil S, Xiao H, Aghalar J, Apollo AJ, Carlo MI, Motzer RJ, Voss MH. Everolimus plus bevacizumab is an effective first-line treatment for patients with advanced papillary variant renal cell carcinoma: Final results from a phase II trial. Cancer. 2020 Dec 15;126(24):5247-5255. doi: 10.1002/cncr.33148.
  3. Jain T, Knezevic A, Pennisi M, Chen Y, Ruiz JD, Purdon TJ, Devlin SM, Smith M, Shah GL, Halton E, Diamonte C, Scordo M, Sauter CS, Mead E, Santomasso BD, Palomba ML, Batlevi CW, Maloy MA, Giralt S, Smith E, Brentjens R, Park JH, Perales MA, Mailankody S. Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies. Blood Adv. 2020 Aug 11;4(15):3776-3787. doi: 10.1182/bloodadvances.2020002509.
  4. Ged Y, Chen YB, Knezevic A, Casuscelli J, Redzematovic A, DiNatale RG, Carlo MI, Lee CH, Feldman DR, Patil S, Hakimi AA, Russo P, Motzer RJ, Voss MH. Metastatic Chromophobe Renal Cell Carcinoma: Presence or Absence of Sarcomatoid Differentiation Determines Clinical Course and Treatment Outcomes. Clin Genitourin Cancer. 2019 Jun;17(3):e678-e688. doi: 10.1016/j.clgc.2019.03.018.
  5. Carlo MI, Mukherjee S, Mandelker D, Vijai J, Kemel Y, Zhang L, Knezevic A, Patil S, Ceyhan-Birsoy O, Huang KC, Redzematovic A, Coskey DT, Stewart C, Pradhan N, Arnold AG, Hakimi AA, Chen YB, Coleman JA, Hyman DM, Ladanyi M, Cadoo KA, Walsh MF, Stadler ZK, Lee CH, Feldman DR, Voss MH, Robson M, Motzer RJ, Offit K. Prevalence of Germline Mutations in Cancer Susceptibility Genes in Patients With Advanced Renal Cell Carcinoma. JAMA Oncol. 2018 Sep 1;4(9):1228-1235. doi: 10.1001/jamaoncol.2018.1986.

View a full listing of Andrea Knezevic’s journal articles.